Navigation Links
Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
Date:4/18/2012

SEATTLE, April 18, 2012 /PRNewswire/ -- On Thursday, April 19, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call.

Conference Call Numbers

Thursday, April 19
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-941-8609 (US Participants)
1-480-629-9692 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:
1-800-406-7325 (US Participants)
1-303-590-3030 (International)
Passcode: 4531446 #

Live audio webcast at www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

Media Contact:

 

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: deramian@ctiseattle.com

www.celltherapeutics.com/press_room

 

Investors Contact:

 

Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

www.celltherapeutics.com/investors

 


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
(Date:3/28/2017)... BOSTON , March 28, 2017  Market ... today announced a partnership with premium news content ... pharmaceutical companies to extract key insights from Dow ... mining technology. The Linguamatics I2E platform ... 20 global pharmaceutical companies. The Linguamatics-Dow Jones partnership ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul ... , WHAT: , Medical doctors and PhD scientists will speak to the press on ... Trump in support of an independent vaccine safety commission. , WHERE: , Zenger ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management Association (RBMA) ... as its new executive director. Mr. Still was selected through a careful months-long search ... as he is known to our members, has been a part of building the ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... MA (PRWEB) , ... March 28, 2017 , ... ... for direct measurement of corrosive ions found in power plant water and steam. ... components such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. ...
Breaking Medicine News(10 mins):